|September 03, 2002
|Hemispherx Biopharma Will Be Presenting at The Wall Street Analyst Forum in New York on September 9, 2002
|Philadelphia, PA, Tuesday, September 03, 2002: Hemispherx Biopharma, Inc. (AMEX: HEB), a biopharmaceutical company focused in the experimental-stage development of immune-based therapies primarily addressing the diseases of HIV AIDS and Chronic Fatigue Syndrome, today announced that Dr. William Carter, Chairman and CEO of Hemispherx, will present to the investment community on Monday, September 9, 2002, at 11:40 AM EDT, at The Wall Street Analyst Forum’s Institutional Investor Conference in New York City at the Roosevelt Hotel.
Analysts and portfolio managers who wish to attend the presentation should contact The Wall Street Analyst Forum at (802) 253-7596, or Dianne Will, Investor Relations for Hemispherx, at (518) 398-6222 to request additional information. Investors may access an Internet webcast of the presentation through Hemispherx Biopharma’s website at:
A replay of the presentation will also be available on the Company’s website for fifteen days following the presentation.
Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system inlcuding, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company's Web site at www.hemispherx.net.
Hemispherx Biopharma, Inc., Investor Relations
(215) 988-1712, Fax: (215) 988-1554
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223
Robert Giordano, MRB Institutional Investors, MRB
(212) 495-0200, Fax: (212) 495-0746
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commisison. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.